Our study shows that patients receiving a continuous infusion of high-dose doxorubicin (90 mg/m2 per cycle for up to a total of 6 cycles) with a median cumulative dose around 500 mg/m2 (majority getting a total of 540 mg/m2) did not experience any significant early evidence of cardiotoxicity (based on LVEF, BNP, and troponin I assessment) or clinical heart failure during the available follow-up period of 3.7 years (range, 1 month to 10.4 years). The gene discussed is NPPB; the disease is heart failure.